All articles tagged with #glp 1 pill
European markets closed mixed with Novo Nordisk shares jumping 9.2% after FDA approval for a GLP-1 pill, while Sanofi announced a $2.2 billion acquisition. Gold and silver futures hit new highs, and U.S. visa bans were imposed on EU officials involved in social media censorship. Asia-Pacific markets traded mostly higher, and U.S. futures remained flat despite record closes for the S&P 500.
The FDA has approved the first oral GLP-1 pill for weight loss, developed by Novo Nordisk, which offers a more convenient and potentially cheaper alternative to injections, with clinical trials showing significant weight loss results.
The FDA has approved the first oral GLP-1 pill for obesity from Novo Nordisk, expected to launch in early 2026, offering a new treatment option that could expand access and compete with Eli Lilly in the booming weight loss drug market.
Eli Lilly's experimental oral GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight in a late-stage trial, with significant improvements in blood sugar levels, positioning it as a promising alternative to injectable obesity drugs and potentially paving the way for regulatory approval and market launch next year.
Eli Lilly's experimental GLP-1 pill, forforglipron, showed promising results in an 18-month trial, with about 60% of participants losing at least 10% of their body weight and an average loss of over 12%, offering a potential alternative to existing obesity treatments.